TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23537882

Group type: EXPERIMENTAL
Intervention: Supervised exercise programme (12-week, twice-weekly)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 156
Study: 21806298

Group type: EXPERIMENTAL
Intervention: 6-week cognitive-behavioral intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual home visiting services (Control)
Number of subjects: 61
Study: 19780539

Group type: EXPERIMENTAL
Intervention: sucrose milk protein (BSMP)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: non-nutritive sweetener milk protein (BNMP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: high milk protein (CMP)
Number of subjects: 6

Group type: COMPARATOR
Intervention: reference dark chocolate (CDK)
Number of subjects: 6
Study: 16113035

Group type: EXPERIMENTAL
Intervention: Twin Block (TB) functional appliance
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 38
Study: 15308927

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11822612

Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medical acupuncture treatment using an average of 12-13 needles per treatment, with more than 85 different acupoints utilized.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Adjunctive treatments including heat (36%-67%) and cupping (16%-21%).
Number of subjects: 150
Study: 9809707

Group type: EXPERIMENTAL
Intervention: tirilazad mesylate
Number of subjects: 0
Study: 7877115

Group type: EXPERIMENTAL
Intervention: Adrenomedullary system activation measured by norepinephrine (NE) and normetanephrine excretion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unipolar depression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bipolar depression
Number of subjects: 0
Study: 3278694

Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 0
Study: 31696972

Group type: EXPERIMENTAL
Intervention: Low-intensity cognitive behavioural therapy (LICBT)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Pre-treatment variables (unemployment, suicide risk, neglect, medication, previous or concurrent treatments, longer duration of difficulties, comorbidities)
Number of subjects: 253
Study: 29380013

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg Q6M for 10 years
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg Q6M for 7 years
Number of subjects: 12
Study: 28664242

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m2 once weekly for 4 weeks)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 51
Study: 24902673

Group type: EXPERIMENTAL
Intervention: Qigong (64 patients, 12 sessions of 90 min/week for 3 months)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Exercise therapy (63 patients, 12 sessions of 60 min/week for 3 months)
Number of subjects: 127
Study: 23435876

Group type: EXPERIMENTAL
Intervention: 1,25-D3 (calcitriol) at 60 mcg/m2 every 21 days with cisplatin 75 mg/m2 and docetaxel 75 mg/m2
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CYP24A1 SNP rs3787554 (C > T)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: CYP24A1 SNP rs2762939 (C > G)
Number of subjects: 34
Study: 21549515

Group type: EXPERIMENTAL
Intervention: Partnered females
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Partnered males
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Unpartnered females
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: White females
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Non‐white males
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Partnered whites
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Unpartnered males
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: White males
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Unpartnered whites
Number of subjects: 1736
Study: 18458207

Group type: EXPERIMENTAL
Intervention: Eszopiclone (3 mg nightly for 8 weeks) + Escitalopram (10 mg for 10 weeks)
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Eszopiclone + Escitalopram
Number of subjects: 595

Group type: COMPARATOR
Intervention: Placebo + Escitalopram
Number of subjects: 595
Study: 16453155

Group type: EXPERIMENTAL
Intervention: (18)F-FDG PET/CT
Number of subjects: 28

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 28
Study: 14990264

Group type: EXPERIMENTAL
Intervention: Glycyl-glutamine-supplemented parenteral nutrition (20 g of glutamine)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard glutamine-free parenteral nutrition
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Glycyl-glutamine-supplemented parenteral nutrition
Number of subjects: 54
Study: 11380464

Group type: EXPERIMENTAL
Intervention: 7‐3 plus high‐dose cytarabine (HIDAC‐3‐7) chemotherapy
Number of subjects: 470

Group type: COMPARATOR
Intervention: 7‐3 chemotherapy (standard dose cytarabine and daunorubicin)
Number of subjects: 470

Group type: COMPARATOR
Intervention: 7‐3 plus etoposide (7‐3‐7) chemotherapy
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Allogeneic transplantation in first CR
Number of subjects: 470
Study: 9052890

Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (calcium channel blocker)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Atenolol (beta-blocker)
Number of subjects: 34
Study: 7639352

Group type: EXPERIMENTAL
Intervention: BN 52021 (120 mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 3351343

Group type: EXPERIMENTAL
Intervention: 5 French catheters (group I)
Number of subjects: 200

Group type: COMPARATOR
Intervention: 8 French catheters (group II)
Number of subjects: 200
Study: 31451130

Group type: EXPERIMENTAL
Intervention: Intranasal midazolam (0.2 mg/kg)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Intranasal ketamine (4 mg/kg)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate (50 mg/kg)
Number of subjects: 217
Study: 27568351

Group type: EXPERIMENTAL
Intervention: High molecular weight Sodium Hyaluronate (3%) plus saline solution (3 mL sodium chloride-NaCl-0.9%) using a nebulizer ampoule for nasal douche, administered twice a day for 30 days.
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline solution (6 mL sodium chloride-NaCl-0.9%) using a nebulizer ampoule for nasal douche, administered twice a day for 30 days.
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups received Levofloxacin (500 mg for 10 days) and Prednisone (50 mg for 8 days, 25 mg for 4 days, and 12.5 mg for 4 days).
Number of subjects: 48
Study: 26258474

Group type: EXPERIMENTAL
Intervention: Intermittent Screening and Treatment with artemether-lumefantrine (ISTp-AL)
Number of subjects: 5354

Group type: COMPARATOR
Intervention: Intermittent Preventive Treatment with sulfadoxine-pyrimethamine (IPTp-SP)
Number of subjects: 5354
Study: 23010608

Group type: EXPERIMENTAL
Intervention: Multifaceted prospective memory intervention delivered by nurses in the home.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education control group.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multifaceted prospective memory intervention.
Number of subjects: 0
Study: 21781652

Group type: EXPERIMENTAL
Intervention: Hydralazine 182 mg/day for fast acetylators
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hydralazine 83 mg/day for slow acetylators
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hydralazine 182 mg/day for cancer patients (fast acetylators)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hydralazine 83 mg/day for cancer patients (slow acetylators)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Hydralazine for healthy volunteers (fast acetylators)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Hydralazine for healthy volunteers (slow acetylators)
Number of subjects: 85
Study: 19349894

Group type: EXPERIMENTAL
Intervention: Oral arginine supplementation (36.2 g of l-arginine-HCl)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (51.2 g alanine)
Number of subjects: 18
Study: 17968821

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Glycerol
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Dexamethasone plus Glycerol
Number of subjects: 654

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study: 15961217

Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (RTX) 50 nM dissolved in 10% ethanol in saline
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (vehicle solution)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (RTX)
Number of subjects: 28
Study: 12009347

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/day) for 6 months
Number of subjects: 10
Study: 9538966

Group type: EXPERIMENTAL
Intervention: Insulin lispro administered 10 min preprandial
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin lispro administered 20 min postprandial
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin lispro administered preprandially with high-carbohydrate meals
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Insulin lispro administered preprandially with solid high-fat meal
Number of subjects: 20
Study: 7480971

Group type: EXPERIMENTAL
Intervention: Taurine administered intravenously before and during anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no taurine)
Number of subjects: 60
Study: 2964388

Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-fluorouracil (5-FU) or 5-fluorouracil-deoxyribose as single agents or in combination with other drugs
Number of subjects: 9
Study: 30106534

Group type: EXPERIMENTAL
Intervention: Occluding toothpaste (8% strontium acetate, 1,040 ppm fluoride)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-occluding toothpaste (1,450 ppm fluoride)
Number of subjects: 20
Study: 29200982

Group type: EXPERIMENTAL
Intervention: Native whey protein (2×20 g)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: WPC‐80 (2×20 g)
Number of subjects: 24
Study: 26286331

Group type: EXPERIMENTAL
Intervention: Self-development coaching programme (two-day workshop)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Active placebo programme (five-hour workshop)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Self-development coaching programme
Number of subjects: 317

Group type: COMPARATOR
Intervention: Active placebo programme
Number of subjects: 317
Study: 23059756

Group type: EXPERIMENTAL
Intervention: Single oral dose of chondroitin 4&6 sulfate 1200 mg (CS 1200)
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Three daily capsules of chondroitin 4&6 sulfate 400 mg (CS 3*400)
Number of subjects: 353

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 353
Study: 20204928

Group type: EXPERIMENTAL
Intervention: Loss-framed message for high self-efficacy participants
Number of subjects: 124

Group type: COMPARATOR
Intervention: Gain-framed message for low self-efficacy participants
Number of subjects: 124
Study: 17682008

Group type: EXPERIMENTAL
Intervention: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + triamcinolone 40 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: GONB and TPIs using lidocaine 2% and bupivacaine 0.5% + saline
Number of subjects: 37
Study: 16620867

Group type: EXPERIMENTAL
Intervention: Scene analogy problems with varying relational complexity and featural distraction
Number of subjects: 5
Study: 14587650

Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Metoprolol (12.5 mg)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional treatment only (Control group)
Number of subjects: 105
Study: 10988306

Group type: EXPERIMENTAL
Intervention: Preoperative autologous blood donation
Number of subjects: 10

Group type: COMPARATOR
Intervention: Acute normovolemic hemodilution
Number of subjects: 10
Study: 8971296

Group type: EXPERIMENTAL
Intervention: Oral erythromycin (160 mg/h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 1361206

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bisoprolol 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg
Number of subjects: 12
Study: 6470470

Group type: EXPERIMENTAL
Intervention: Short-term psychoeducational group intervention 'Seminars for the Separated'
Number of subjects: 314

Group type: COMPARATOR
Intervention: Control group (married subjects)
Number of subjects: 314
Study: 30113633

Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 1212

Group type: COMPARATOR
Intervention: Medical therapy (MED)
Number of subjects: 1212
Study: 27473400

Group type: EXPERIMENTAL
Intervention: Monthly payment disbursement
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Semi-monthly payment disbursement
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (normal cheque issue)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: All intervention arms (monthly and semi-monthly)
Number of subjects: 273
Study: 24345483

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (OBA)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo (saline injections)
Number of subjects: 85
Study: 22648836

Group type: EXPERIMENTAL
Intervention: Lipoplus
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lipofundin
Number of subjects: 64
Study: 20495474

Group type: EXPERIMENTAL
Intervention: On-site, nurse-administered intervention
Number of subjects: 163

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 163
Study: 18359168

Group type: EXPERIMENTAL
Intervention: Psychosocial stress (Trier Social Stress Test)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 40
Study: 16013624

Group type: EXPERIMENTAL
Intervention: Pilot-hole size 2.5 mm
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pilot-hole size 3.2 mm
Number of subjects: 25
Study: 14564334

Group type: EXPERIMENTAL
Intervention: Hydrotherapy (6 weeks of intensive home-based hydrotherapy)
Number of subjects: 15
Study: 10981255

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 0
Study: 8888380

Group type: EXPERIMENTAL
Intervention: m-CPP (0.08 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1285042

Group type: EXPERIMENTAL
Intervention: Intra-operative autologous transfusion (IOAT)
Number of subjects: 0
Study: 6591741

Group type: EXPERIMENTAL
Intervention: iohexol 240 mg I/ml
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: iohexol 300 mg I/ml
Number of subjects: 51

Group type: COMPARATOR
Intervention: metrizoate 200 mg I/ml
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: iohexol 240 mg I/ml and iohexol 300 mg I/ml
Number of subjects: 51
Study: 31321915

Group type: EXPERIMENTAL
Intervention: Assisted partner notification services (aPNS)
Number of subjects: 0
Study: 28387833

Group type: EXPERIMENTAL
Intervention: Naltrexone (opioid antagonist)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 27527342

Group type: EXPERIMENTAL
Intervention: Partial caries removal followed by adhesive restoration
Number of subjects: 464

Group type: COMPARATOR
Intervention: Complete caries removal followed by adhesive restoration
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Antibacterial adhesive system
Number of subjects: 464

Group type: COMPARATOR
Intervention: Traditional two-step self-etch adhesive system
Number of subjects: 464
Study: 24509027

Group type: EXPERIMENTAL
Intervention: Culturally sensitive, empowerment-focused, community-based health promotion program
Number of subjects: 130

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 130
Study: 22198776

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg rectally 30 to 60 minutes before ERCP plus somatostatin 0.25 mg/h for 6 hours
Number of subjects: 540

Group type: COMPARATOR
Intervention: Placebo suppository and saline solution
Number of subjects: 540
Study: 21034824

Group type: EXPERIMENTAL
Intervention: Recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, administered at 2×10(9) viral particles (n=12)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Recombinant adenovirus serotype 5 (rAd5) vaccine encoding the envelope glycoprotein (GP) from the Zaire and Sudan Ebola virus species, administered at 2×10(10) viral particles (n=11)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (n=8)
Number of subjects: 31
Study: 17413885

Group type: EXPERIMENTAL
Intervention: Abdominoplasty
Number of subjects: 12

Group type: COMPARATOR
Intervention: Noninterventional group
Number of subjects: 12
Study: 16669149

Group type: EXPERIMENTAL
Intervention: Total fundoplicature (Group II)
Number of subjects: 285

Group type: COMPARATOR
Intervention: Anterior partial fundoplication (Group II)
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (both groups)
Number of subjects: 285
Study: 11955470

Group type: EXPERIMENTAL
Intervention: ECT
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 41
Study: 11131271

Group type: EXPERIMENTAL
Intervention: Temocapril, 2 to 4 mg once daily for 12 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Diuretic (trichlormethiazide) continued for an additional 12 months
Number of subjects: 76
Study: 8825539

Group type: COMPARATOR
Intervention: Local infiltration with lidocaine 1% with adrenaline 1:200,000, 0.4 ml.kg‐1 (n = 21)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nerve blockade with bupivacaine 0.5%, 0.4 ml.kg‐1 (n = 22)
Number of subjects: 43
Study: 1433739

Group type: EXPERIMENTAL
Intervention: Special Intervention (SI) group
Number of subjects: 5524

Group type: COMPARATOR
Intervention: Usual Care (UC) group
Number of subjects: 5524

Group type: EXPERIMENTAL
Intervention: Combined groups (SI and UC) with diastolic blood pressure maintained below 95 mm Hg
Number of subjects: 5524

Group type: EXPERIMENTAL
Intervention: Participants with blood pressure ≥ 95 mm Hg
Number of subjects: 5524

Group type: EXPERIMENTAL
Intervention: Black men (n = 463)
Number of subjects: 5524
Study: 2990260

Group type: EXPERIMENTAL
Intervention: Electrostimulation (group I)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (group II)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups received the same drugs (droperidol, flunitrazepam, pancuronium, nitrous oxide with oxygen)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 30096245

Group type: EXPERIMENTAL
Intervention: Glucose preload (200 kcal)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sucralose preload (0 kcal)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Video game playing (30 min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No video game playing (control condition)
Number of subjects: 22
Study: 29063860

Group type: EXPERIMENTAL
Intervention: Voxilaprevir (VOX) 100 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Voxilaprevir (VOX)
Number of subjects: 66
Study: 27448838

Group type: EXPERIMENTAL
Intervention: Preoperative educational intervention (KTFI)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Routine preoperative education (Control Group)
Number of subjects: 100
Study: 25223172

Group type: EXPERIMENTAL
Intervention: Kuntai Capsule (KC)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 22578567

Group type: EXPERIMENTAL
Intervention: Subtotal Le Fort I osteotomy (Group I)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subtotal Le Fort I osteotomy without pterygomaxillary suture disjunction (Group II)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Subtotal Le Fort I osteotomy with pterygomaxillary suture disjunction and fixation of the anterior nasal spine with steel wire (Group III)
Number of subjects: 6
Study: 20207828

Group type: EXPERIMENTAL
Intervention: GLP‐1 (1.2 pmol/kg · min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 9
Study: 17679728

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily for 16 weeks + gefitinib 250 mg/d orally for 16 weeks
Number of subjects: 206

Group type: COMPARATOR
Intervention: Anastrozole 1 mg daily for 16 weeks
Number of subjects: 206
Study: 15671611

Group type: EXPERIMENTAL
Intervention: Tc‐99m‐sestamibi imaging
Number of subjects: 29

Group type: COMPARATOR
Intervention: PET
Number of subjects: 29
Study: 11849904

Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (MI)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 109
Study: 10190536

Group type: EXPERIMENTAL
Intervention: Alternate-day simvastatin and fenofibrate therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard daily combination of simvastatin and fenofibrate
Number of subjects: 0
Study: 7799040

Group type: EXPERIMENTAL
Intervention: Very low-dose warfarin (VLDW)
Number of subjects: 100
Study: 2328303

Group type: EXPERIMENTAL
Intervention: Pelletised doxycycline with food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pelletised doxycycline without food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reference product without food
Number of subjects: 0
Study: 31173679

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (4000 IU per day)
Number of subjects: 2423

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2423
Study: 29045529

Group type: EXPERIMENTAL
Intervention: FOLFIRI and bevacizumab (FOLFIRI/bev)
Number of subjects: 567

Group type: COMPARATOR
Intervention: FOLFIRI and cetuximab (FOLFIRI/cet)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Combined FOLFIRI/bev cohorts
Number of subjects: 567
Study: 25962515

Group type: EXPERIMENTAL
Intervention: OPTIMAL (occupational therapy led self-management support programme)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: OPTIMAL
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 24021347

Group type: EXPERIMENTAL
Intervention: 38-h communication skills training program
Number of subjects: 80
Study: 22185865

Group type: EXPERIMENTAL
Intervention: Low-dose multidetector computed tomography (CT) screening
Number of subjects: 7557

Group type: COMPARATOR
Intervention: Control group without screening
Number of subjects: 7557
Study: 19728556

Group type: EXPERIMENTAL
Intervention: MetraTRAP5b assay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BoneTRAP® assay
Number of subjects: 0